Hypothesis

Intermittent, doxycycline‑inducible OSK expression paired with periodic senolytic treatment yields longer‑lasting age‑reversal effects than continuous OSK alone, without increasing tumorigenic risk.

Rationale

• Partial reprogramming with OSK extends lifespan and improves frailty, but benefits fade when expression stops [2], 3], suggesting that the epigenetic reset is not self‑maintaining.
• Senescent cells accumulate with age and secrete a SASP that activates inflammatory pathways (e.g., cGAS‑STING, NF‑κB) which can impede reprogramming efficiency and increase DNA damage [5].
• Removing senescent cells lowers SASP burden, reduces innate immune activation, and creates a more permissive chromatin environment for factor‑driven epigenetic remodeling.
• An inducible system allows tight control of OSK dosage, limiting exposure time and thereby reducing the risk of insertional mutagenesis or oncogenic transformation that accompanies prolonged expression.

Testable Predictions

1. In aged mice, a regimen of two‑week OSK induction every four weeks combined with quarterly senolytic (e.g., dasatinib + quercetin) dosing will produce a greater increase in median remaining lifespan than either continuous OSK or senolytic monotherapy.
2. Epigenetic clocks (e.g., Horvath mouse clock) will show sustained reversal throughout the observation period only in the combined group, whereas OSK‑only groups revert to baseline after each induction cycle.
3. Tumor incidence (histopathology of liver, lung, lymphoma) will not exceed that of control animals, indicating that intermittent expression mitigates oncogenic risk.
4. Serum SASP markers (IL‑6, TNF‑α, MMP‑9) will be significantly lower in the combined group compared with OSK‑only, supporting the mechanistic link between senescent‑cell clearance and improved reprogramming tolerance.

Experimental Design

• Animals: 24‑month‑old C57BL/6J mice, n=15 per group.
• Groups: (1) Vehicle control, (2) Continuous OSK (doxycycline in water), (3) Intermittent OSK (2 weeks on/2 weeks off), (4) Senolytic only (dasatinib + quercetin 5 mg/kg each, i.p., weekly), (5) Combined intermittent OSK + senolytic (same schedule as OSK intermittent, senolytic given 24 h after each OSK induction week).
• Readouts: Survival, frailty index, grip strength, MRI‑based tissue volumetry, epigenetic clock analysis from liver and blood, tumor histopathology, cytokine profiling.
• Statistical analysis: Kaplan‑Meier with log‑rank test for survival; ANOVA with post‑hoc Tukey for continuous endpoints; significance set at p<0.05.

Falsifiability

If the combined regimen fails to outperform monotherapies in lifespan extension, epigenetic clock reversal, or shows increased tumorigenicity, the hypothesis is falsified. Conversely, a clear advantage would support the idea that temporal separation of reprogramming pressure and senescent‑cell burden creates a synergistic, safer rejuvenation strategy.

Broader Impact

Demonstrating that safety and efficacy can be balanced through controlled, intermittent factor exposure may inform the design of future gene‑therapy‑based aging interventions, reducing the temptation for uncontrolled self‑experimentation while providing a rigorous, translatable path forward.